Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non–small-Cell Lung Cancer Treated With Pembrolizumab
Thomas Jemielita(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cong Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kai‐Li Liaw(United States Military Academy), Thomas Burke(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaoyun Li(Nanjing University), Wei Zhou(Broad Institute)
Cited by 3
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers
|New England Journal of Medicine|2011|1.1k